Jaroslav Michalek1,2, Zuzana Dudasova1,2* and Conville Brown1,3
1International Consortium for Cell Therapy and Immunotherapy, Czech Republic
2Cellthera Clinic, Czech Republic
3The Partners Stem Cell Centre, The Bahamas
Idiopathic Pulmonary Fibrosis is a progressive lung disease with unknown origin, poor prognosis and limited treatment options. A strategy implementing autologous Stromal Vascular Fraction (SVF) cells from adipose tissue represents a novel approach in this chronic and devastating disease. Here we present a case study of a 71 year old woman who underwent SVF cell therapy during one surgical procedure. Clinical status of the patient was closely monitored with regular spirometry before and up to 14 months after SVF cell therapy. Nine months after SVF therapy patient did not require anti-fibrotic drugs and spirometry showed improvements that continued further at 14 months. SVF therapy is a rapid, safe, and cost-effective method which can be easily applied in patients with pulmonary fibrosis and other chronic lung diseases.
Idiopathic pulmonary fibrosis; Chronic lung disease; Chronic asthma; Stromal vascular fraction; Stem cells
Michalek J, Dudasova Z, Brown C. Stromal Vascular Fraction Cell Therapy for Idiopathic Pulmonary Fibrosis - Cure without Side Effects. Ann Clin Case Rep. 2019; 4: 1698 .